April 3, 2020 -- Modalis Therapeutics has licensed intellectual property (IP) from CRISPR-related gene-editing company Editas Medicine.
Through the agreement, Modalis will use CRISPR-Guide Nucleotide Directed Modulation (CRISPR-GNDM) technology to create gene therapies for patients with genetic disorders. Financial terms of the agreement were not disclosed.